Rigel Pharmaceuticals, Inc. Annual report pursuant to Section 13 and 15(d)

Annual report pursuant to Section 13 and 15(d)

Cover
- DOCUMENT AND ENTITY INFORMATION
Financial Statements
Notes to Financial Statements
Accounting Policies
- SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)
Notes Tables
Notes Details

SPONSORED RESEARCH AND LICENSE AGREEMENTS (Details)

v3.8.0.1

SPONSORED RESEARCH AND LICENSE AGREEMENTS (Details) - USD ($)	1 Months Ended					3 Months Ended		12 Months Ended
	Feb. 28, 2017	Dec. 31, 2016	Jun. 30, 2016	Sep. 30, 2015	Mar. 31, 2015	Mar. 31, 2017	Jun. 30, 2016	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2017	Sep. 30, 2016
Collaborative arrangement
Collaborations
Maximum amount of contingent payments receivable										$ 532,400,000
BerGenBio A S Worldwide License Agreement
Collaborations
Revenue recognized							$ 3,700,000
Specified Development Events \| Collaborative arrangement
Collaborations
Maximum amount of contingent payments receivable										145,500,000
Specified Regulatory Events \| Collaborative arrangement
Collaborations
Maximum amount of contingent payments receivable										345,600,000
Specified Product Launch Events \| Collaborative arrangement
Collaborations
Maximum amount of contingent payments receivable										$ 41,300,000
Bristol-Myers Squibb Company
Collaborations
Upfront fee received					$ 30,000,000
Contingent payments									$ 309,000,000
Deferred revenue related to upfront payment											$ 30,000,000
Revenue recognized		$ 3,000,000						$ 13,400,000	16,600,000
Bristol-Myers Squibb Company \| Research Activities
Collaborations
Revenue recognized								$ 290,000	822,000
Aclaris
Collaborations
Upfront fee received				$ 8,000,000
Contingent payments									80,000,000
Revenue recognized									$ 8,000,000
BerGenBio
Collaborations
Upfront fee received			$ 1,700,000
Collaborative payment received	$ 3,300,000
Revenue recognized						$ 3,300,000
Payment received from exercise of option rights			$ 2,000,000

- Definition

Represents the amount of deferred revenue as of balance sheet date related to upfront payment under the collaborative and licensing agreement.

+ References

No definition available.

+ Details

Name:	rigl_CollaborativeArrangementDeferredRevenueRelatedToUpfrontPayment
Namespace Prefix:	rigl_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Represents the maximum amount of pre-specified contingent payments receivable under the collaborative and licensing agreement.

+ References

No definition available.

+ Details

Name:	rigl_CollaborativeArrangementMaximumAmountOfContingentPaymentReceivable
Namespace Prefix:	rigl_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Represents payments received from exercise of option rights.

+ References

No definition available.

+ Details

Name:	rigl_CollaborativeArrangementOptionRightsExercised
Namespace Prefix:	rigl_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Represents the amount of collaboration payment received during the period.

+ References

No definition available.

+ Details

Name:	rigl_CollaborativeArrangementPaymentsReceived
Namespace Prefix:	rigl_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Represents the revenue recognized during the period under the terms of sponsored research and license agreements.

+ References

No definition available.

+ Details

Name:	rigl_CollaborativeArrangementRevenueRecognized
Namespace Prefix:	rigl_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Represents the amount of upfront fees received during the period under the terms of collaborative and licensing agreement.

+ References

No definition available.

+ Details

Name:	rigl_CollaborativeArrangementUpfrontFeeReceived
Namespace Prefix:	rigl_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Represents additional contingent payments by entities.

+ References

No definition available.

+ Details

Name:	rigl_ContingentPaymentsUnderAgreement
Namespace Prefix:	rigl_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

No definition available.

+ Details

Name:	us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Details

Name:	us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=rigl_BerGenBioASWorldwideLicenseAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	rigl_AchievementOfMilestoneAxis=rigl_SpecifiedDevelopmentEventsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	rigl_AchievementOfMilestoneAxis=rigl_SpecifiedRegulatoryEventsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	rigl_AchievementOfMilestoneAxis=rigl_SpecifiedProductLaunchEventsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	dei_LegalEntityAxis=rigl_BristolMyersSquibbCompanyMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	rigl_AchievementOfMilestoneAxis=rigl_ResearchActivitiesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	dei_LegalEntityAxis=rigl_AclarisTherapeuticsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	dei_LegalEntityAxis=rigl_BerGenBioASMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type: